Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair

Eleftherios A. Makris, Regina F. MacBarb, Nikolaos K. Paschos, Jerry C. Hu, Kyriacos A. Athanasiou

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.

Original languageEnglish (US)
Pages (from-to)6787-6796
Number of pages10
JournalBiomaterials
Volume35
Issue number25
DOIs
StatePublished - 2014

Fingerprint

Protein-Lysine 6-Oxidase
Fibrocartilage
Chondroitin ABC Lyase
Collagen
Crosslinking
Repair
Engineers
Tensile Strength
Tissue
Defects
Elastic Modulus
Therapeutics
Mechanics
Tensile properties
Scaffolds
Tensile strength
Elastic moduli
Stiffness
Technology
Oxidoreductases

Keywords

  • Collagen crosslinking
  • Fibrocartilage
  • Integration
  • Lysyl oxidase
  • Tissue engineering

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics
  • Medicine(all)

Cite this

Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair. / Makris, Eleftherios A.; MacBarb, Regina F.; Paschos, Nikolaos K.; Hu, Jerry C.; Athanasiou, Kyriacos A.

In: Biomaterials, Vol. 35, No. 25, 2014, p. 6787-6796.

Research output: Contribution to journalArticle

Makris, Eleftherios A. ; MacBarb, Regina F. ; Paschos, Nikolaos K. ; Hu, Jerry C. ; Athanasiou, Kyriacos A. / Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair. In: Biomaterials. 2014 ; Vol. 35, No. 25. pp. 6787-6796.
@article{ee1277cca03f4b1e940628a79ff8c433,
title = "Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair",
abstract = "Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245{\%} and 186{\%}, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730{\%} and 745{\%}, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.",
keywords = "Collagen crosslinking, Fibrocartilage, Integration, Lysyl oxidase, Tissue engineering",
author = "Makris, {Eleftherios A.} and MacBarb, {Regina F.} and Paschos, {Nikolaos K.} and Hu, {Jerry C.} and Athanasiou, {Kyriacos A.}",
year = "2014",
doi = "10.1016/j.biomaterials.2014.04.083",
language = "English (US)",
volume = "35",
pages = "6787--6796",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "25",

}

TY - JOUR

T1 - Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair

AU - Makris, Eleftherios A.

AU - MacBarb, Regina F.

AU - Paschos, Nikolaos K.

AU - Hu, Jerry C.

AU - Athanasiou, Kyriacos A.

PY - 2014

Y1 - 2014

N2 - Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.

AB - Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.

KW - Collagen crosslinking

KW - Fibrocartilage

KW - Integration

KW - Lysyl oxidase

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84902082361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902082361&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.04.083

DO - 10.1016/j.biomaterials.2014.04.083

M3 - Article

C2 - 24840619

AN - SCOPUS:84902082361

VL - 35

SP - 6787

EP - 6796

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 25

ER -